A Chicago woman was just weeks away from giving birth when a nagging cough led to a shocking medical discovery.

MaKenna Lauterbach, then 26 years old, began experiencing severe coughing fits in the last three months of her pregnancy.

“They would be so severe that I would become winded and nauseous to the point of vomiting,” she told Fox News Digital.

PREGNANT WOMAN WITH BRAIN CANCER REFUSES ABORTION

Lauterbach, who lives on a farm in Washburn, Illinois, also began noticing shortness of breath while tending to her horses and goats.

“I give hay to the horses every morning and noticed how winded I was becoming with a dry cough,” she said. “My body felt like I just ran two miles, when, in reality, I had only walked to the barn and back.”

Some doctors dismissed Lauterbach’s symptoms, she said, repeatedly telling her, “It’s because you are pregnant.”

Eventually, though, when the coughing led to vomiting, doctors performed scans and detected a large, grapefruit-sized tumor in her middle chest cavity and right lung, which was completely blocking the artery to the right lung. 

PREGNANT MOM WITH CANCER DEFIED DOCTORS’ ABORTION GUIDANCE

“It’s extremely rare to see this type of tumor invading into the major blood vessels of the heart,” said Chris Mehta, M.D. — a cardiac surgeon with the Northwestern Medicine Bluhm Cardiovascular Institute who specializes in complex heart reconstruction — in a press release. 

“It’s extremely rare to see this type of tumor invading into the major blood vessels of the heart.”

Advertisement

“We may see something like this once every few years.”

The tumor had put Lauterbach — and her baby — into respiratory distress.

‘In real trouble’

Lauterbach was flown to Northwestern Memorial Hospital in Chicago, where a large medical team was waiting for her.

“MaKenna was in real trouble, and we had to act quickly – this wasn’t something that could wait for Monday morning,” said Lynn Yee, M.D., maternal-fetal medicine specialist at Northwestern Medicine, in the release. 

Though he was born three weeks early, little Colter is a thriving, happy baby boy today. “As for myself, I am still healing, emotionally and physically,” said Lauterbach. (MaKenna Lauterbach)

“When you’re pregnant with a baby that’s nearly full term, your lungs already aren’t functioning at full capacity, and when you add a huge tumor on top of it, you run the risk of having respiratory collapse and cardiac arrest.” 

The baby was not tolerating the contractions well and Lauterbach’s blood pressure was plummeting. 

THE YEAR IN CANCER: ADVANCES MADE IN 2024, PREDICTIONS FOR 2025

The team performed an emergency cesarean section — and on Easter Sunday, a healthy baby boy, Colten, was born. 

‘Blindsiding news’

After the delivery, it was time to address the tumor.

“The tumor was sitting on top of MaKenna’s heart and extended into the right lung, impacting all three lobes and the entire main trunk of the pulmonary artery,” said Kalvin Lung, M.D., a thoracic surgeon with the Northwestern Medicine Canning Thoracic Institute, in the release.

Doctors performed a biopsy and diagnosed Lauterbach with stage 3 melanoma.

The Lauterbach family lives on a farm in Washburn, Illinois. MaKenna Lauterbach first experienced severe coughing fits and shortness of breath when tending to the horses and goats. (MaKenna Lauterbach)

The doctors believe she may have had a melanoma on her skin at some point, and that “a cell or two escaped” and began growing inside her body.

“It was truly blindsiding news,” Lauterbach told Fox News Digital. “When I first got the diagnosis, I went through a roller coaster of emotions.”

“I was grieving the birth plan I had spent months preparing, while also dealing with the news of my unexpected diagnosis.”

After first feeling relief at having an answer, she said she felt some anger that her symptoms had been dismissed earlier. Then there was the fear of the cancer itself.

“Because of the tumor, the delivery happened so quickly. I was grieving the birth plan I had spent months preparing, while also dealing with the news of my unexpected diagnosis,” she said.

“My situation was serious, and while my clinical team was working on a plan to treat my cancer, it was comforting to know that the NICU nurses [at Northwestern] were taking such wonderful care of our son.”

Taking life-saving action

The team at Northwestern recommended that Lauterbach undergo three cycles of immunotherapy before surgery, which helped shrink her tumor by 30%.

Dr. Lung and Dr. Mehta removed Lauterbach’s entire right lung, parts of the main pulmonary artery and her lymph nodes. 

The Lauterbach family is pictured with, left to right, Dr. Kalvin Lung, registered nurse Mary Schuessler and Dr. Lynn Yee. (Northwestern Medicine)

“The surgery was risky relative to other cancer surgeries due to the need for cardiopulmonary bypass, and the need to repair the main artery going to both lungs, but it was done under very safe conditions with well-proven techniques,” Dr. Lung told Fox News Digital. 

“We were concerned that even with the extent of surgery, we would not be able to completely remove the tumor,” he went on.

If the tumor had grown just slightly more into the main artery going to the lungs, or if it had involved the heart, it would have been a different outcome.

But the surgery was a success, and Lauterbach’s latest scans showed no evidence of metastatic melanoma.

Colter Lauterbach is pictured with Santa ahead of his first Christmas. (MaKenna Lauterbach)

“Her outcome was very good,” Dr. Lung told Fox News Digital. “She has recovered from surgery almost entirely, and her main issue is shortness of breath, which is a consequence of only having one lung.”

“In terms of cancer prognosis, we expect it to be quite good, given that the entire tumor responded to the immunotherapy treatment she received.” 

‘New normal’

Today, though he was born three weeks early, little Colter Lauterbach is a thriving, happy baby boy.

“As for myself, I am still healing, emotionally and physically,” said MaKenna Lauterbach. “My lung capacity is getting close to ‘the new normal’ for me and I’m finally starting to return to some sort of normal routine.”

“There are some days when the bad memories and the unknowns haunt my thoughts.”

Looking ahead, Lauterbach will continue immunotherapy treatments for one year, and the doctors will continue to monitor CT scans to ensure the cancer doesn’t come back.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Her cancer is currently considered a “stable disease,” doctors say, which means no new tumors have appeared. 

The new mother, who turned 27 in October, said she is looking forward to her son’s first Christmas on the farm.

MaKenna and Parker Lauterbach are pictured with their son, Colter, after he was born by emergency cesarean section. (MaKenna Lauterbach)

“Emotionally, I try my best not to let reality weigh on me, but there are some days when the bad memories and the unknowns haunt my thoughts,” she said.

“Colter and my wonderful husband, Parker, are what have given me the strength to make it through everything.”

For more Health articles, visit www.foxnews.com/health

For other women, Lauterbach emphasized the importance of “knowing your body.”

She advised, “If you know something isn’t right, don’t take ‘I don’t know’ for an answer. Find someone who will take your concerns seriously and would rather do extra testing just in case, as opposed to missing something life-threatening.”

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA).

On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The drug is to be paired with a reduced-calorie diet and increased physical activity, the FDA noted.

SOME SLEEP APNEA PATIENTS SEE IMPROVEMENT WITH NEW BREATHING TOOL

Sally Seymour, M.D., director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research in Washington, D.C., applauded the approval in an announcement.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Seymour wrote. “This is a major step forward for patients with obstructive sleep apnea.”

OSA occurs when the upper airway becomes blocked and causes pauses in breathing during sleep, according to the FDA. The condition is more common in people who are overweight or obese.

UNTREATED SLEEP APNEA PRESENTS ‘DISRUPTIVE’ DANGERS TO PEOPLE’S LIVES, INCLUDING HEART ISSUES, SAYS EXPERT

Similar to semaglutide treatments like Ozempic and Wegovy, Zepbound activates receptors of hormones secreted from the intestine (GLP-1 and GIP) to reduce appetite and food intake.

About 30 million people suffer from sleep apnea in the U.S.

Studies show that by reducing body weight, Zepbound “also improves OSA,” the FDA noted.

In a 52-week study, participants treated with Zepbound experienced “statistically significant and clinically meaningful reduction in events of apnea or hypopnea,” and a large share of participants achieved remission or “resolution of symptoms.”

Zepbound improves obstructive sleep apnea by reducing body weight, studies show. (iStock)

Zepbound-treated patients also reported a significant decrease in body weight, the FDA mentioned.

The drug can reportedly cause side effects like nausea, diarrhea, vomiting, constipation, stomach discomfort and pain, injection site reactions, fatigue, allergic reactions (typically fever and rash), burping, hair loss and gastroesophageal reflux disease.

DO WOMEN NEED MORE SLEEP THAN ME? HERE’S WHAT EXPERTS THINK

While Zepbound causes thyroid C-cell tumors in rats, it’s unknown whether it causes these tumors in humans, so it should not be used by patients with a personal or family history of medullary thyroid cancer or with multiple endocrine neoplasia syndrome type 2, per the FDA.

The agency encourages all OSA patients to consult with a doctor before taking Zepbound and to monitor for any complications.

One sleep expert called the FDA’s approval a “promising advancement for the millions of people who suffer from this condition.” (iStock)

Sleep expert Dr. Wendy Troxel, who is a RAND Corporation senior behavioral specialist and licensed clinical psychologist in Utah, called the FDA’s approval a “promising advancement for the millions of people who suffer from this condition.”

“Zepbound promotes weight loss and has been shown to reduce apnea events.”

Advertisement

About 30 million people suffer from sleep apnea in the U.S., Troxel told Fox News Digital.

While the most common treatment for sleep apnea — positive airway pressure (PAP) — is “highly effective” at treating the condition, up to 50% of patients are “non-adherent,” she said.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Zepbound promotes weight loss and has been shown to reduce apnea events,” Troxel noted.

“For obese individuals with moderate to severe sleep apnea, this new treatment option may offer an important alternative or adjunctive treatment, particularly for those who struggle with sleep apnea therapies, such as positive airway pressure.”

People with a history of severe allergic reaction to tirzepatide should not use Zepbound, the FDA warned in a news release. (iStock)

Troxel added that treating sleep apnea is “critical not only for the patient’s health and well-being, but also for their bed partners, who are often the ‘hidden casualties’ of untreated sleep apnea, given that loud snoring and gasping for air are primary symptoms,” she said.

For more Health articles, visit www.foxnews.com/health

Dr. William Lu, medical director of Dreem Health in San Francisco, told Fox News Digital that obesity and sleep apnea are “two of the most prevalent health conditions that affect Americans today.”

“We still need to emphasize shifting the diet and health habits of many, but this is a fantastic start.”

“And they go hand in hand,” he said. “For the patients who qualify and have no contraindications, tirzepatide has the opportunity to be a generational medication that can help people lose weight, reduce the severity of sleep apnea and improve overall health.”

“We still need to emphasize shifting the diet and health habits of many, but this is a fantastic start.”

Getting tested for sleep apnea is “critical for your health,” Lu said, and could also be a requirement for getting coverage for the medication. 

Fox News Digital reached out to Eli Lilly requesting comment.

Renowned visionary English physician William Harvey wrote in 1651 about how our blood contains all the secrets of life.

“And so I conclude that blood lives and is nourished of itself and in no way depends on any other part of the body as being prior to it or more excellent,” he wrote. “So that from this we may perceive the causes not only of life in general … but also of longer or shorter life, of sleeping and waking, of skill, of strength and so forth.”

Dr. Kevin Watt, team leader of the Heart Regeneration and Disease Laboratory at the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia, understands this concept deeply. 

STEM CELL RESEARCH SHOWING NEW POSSIBILITIES FOR TREATING INFANT HEART DISEASE

He lives it every day, as he and his fellow researchers study and reprogram the potential of the blood to treat disease, specifically heart failure in children. 

Building on the work of Dr. Shinya Yamanaka of Japan, who discovered that specialized cells could be reprogrammed back to immature stem cells, Watt and his collaborators have taken this work several steps further. 

They have used small molecules to turn these new stem cells from the blood into heart cells.

Small heart organoids are developed in the lab — which can then be injected into the failing hearts of children. 

BOY FACING BLINDNESS GETS LIFE-CHANGING EYE SURGERY: ‘SUCH A BLESSING’

Relying on the philanthropic support of the Murdoch Institute, the work is progressing rapidly and has been shown to be effective already in mice, pigs and sheep.

“The vision of our research is to develop new therapies that can transform the lives of children with heart failure.”

Clinical trials in humans will be starting soon, and as Dr. Watt told me in an interview from Australia, “Large sheets of heart tissue will be stitched into the failing heart.” 

Congenital heart failure as well as side effects of chemotherapy in children will be targets for this miracle therapy. Millions of children around the world suffer daily from these conditions. 

Researchers at MCRI are studying and reprogramming the potential of the blood to treat disease, specifically heart failure in children.  (MCRI)

Watt said that certain chemotherapy (anthracyclines) have a higher risk of heart failure – up to 15% of the time – and this treatment may be useful to protect the heart.

Watt said, “Heart failure remains an urgent, unmet clinical challenge across the world. While we have made significant advances over several decades in managing the disease, we lack targeted therapies to treat these devastating conditions.”

FAMILY OF CHILD WITH DOWN SYNDROME WENT FROM SHOCK TO GRATITUDE: ‘LOST THE AIR IN MY CHEST’ 

He added, “More than 500,000 children around the world live with advanced heart failure that requires transplantation. The vision of our research is to develop new therapies that can transform the lives of children with heart failure.”

“More than 500,000 children around the world live with advanced heart failure that requires transplantation. The vision of our research is to develop new therapies that can transform the lives of children with heart failure.” (iStock)

To achieve this, he said, “we use a technology called induced pluripotent stem cells, where we can convert blood or skin cells of patients with heart failure into stem cells that we then turn into heart cells … or even make engineered heart tissues that can be stitched onto the patient’s heart to help it pump.” 

The cells that are targeted in the blood are known as peripheral blood mononuclear cells (PBMCs). 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

They are “pushed back in time to an earlier time before they became differentiated into heart or kidney cells,” he said. 

Then they can be pushed forward to become healthy heart cells or mutations — or other abnormalities can be corrected.

While the team at the Murdoch Children’s Research Institute is making heart cells from stem cells in the blood for clinical use, it’s also using these stem cells to figure out new drugs to treat heart failure directly.  

The team at MCRI in Melbourne (shown above) is pioneering “methods to turn stem cells into miniature heart tissues.” (MCRI)

Said Watt, “Using stem cells from patients with heart failure caused by chemo, we are actively developing new drugs and cell-based treatments that we believe will transform the lives of patients with these conditions … Our research group has pioneered methods to turn these stem cells into miniature heart tissues that can be used to model disease-in-a-dish, to identify new drug targets for the development of new therapies.”

These treatments are personalized and highly expensive, but they’re also highly effective. 

“Using stem cells from patients with heart failure caused by chemo, we are actively developing new drugs and cell-based treatments that we believe will transform the lives of patients with these conditions.” (MCRI)

Correcting heart failure in young children is only a few years away from becoming a reality. 

It’s a Christmas miracle that relies on the kind of philanthropic support that MCRI is famous for arranging.

“Philanthropic support plays a critical role in accelerating the development of these new, transformative treatments,” said Watt, “and this support will be essential as we work toward bringing stem cell-based precision therapies for heart failure to every child who needs it.” 

For more Health articles, visit www.foxnews.com/health

Visit go.fox/MCRI to donate or to learn more about MCRI’s important research.